NeuroSense Therapeutics Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-20, consolidating every twenty existing shares into one new share. The effective date for trading on the Nasdaq Capital Market is September 14, 2026. This action reduces the issued and outstanding share count from approximately 37.9 million to roughly 1.9 million, with fractional shares rounded up to the nearest whole share rather than paid in cash. Outstanding warrants and options will receive proportionate adjustments to their exercise prices and share counts. The company operates in the biotechnology industry, focusing on developing therapeutic treatments for neurological disorders.

On August 26, 2026, shareholders of NeuroSense Therapeutics Ltd. approved a board authorization to effect one or more reverse share splits at an aggregate ratio ranging from 1-for-4 to 1-for-40. The exact ratio and effective date will be determined by the Board within 12 months. No amendment to the Articles of Association is required for this action. This company operates in the biotechnology industry, focusing on drug discovery.

CEO Alon Ben-Noon announced that NeuroSense Therapeutics is preparing to initiate its pivotal Phase 3 PARAGON study for PrimeC in ALS, which will enroll approximately 300 participants. Securing financing has taken longer than anticipated; however, the CEO and CFO each invested $200,000 in April 2026 alongside a significant existing investor. The company is pursuing strategic partnerships and non-dilutive funding while preparing a New Drug Submission to Health Canada for December 2026 based on Phase 2b data. To address Nasdaq listing deficiencies regarding the minimum bid price, an upcoming shareholder meeting will include a proposal authorizing the Board to effect a reverse share split within a range of 1:4 to 1:40 if necessary. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases.

NeuroSense Therapeutics completed its Pre-New Drug Submission (Pre-NDS) process with Health Canada for PrimeC, its lead therapeutic candidate for amyotrophic lateral sclerosis (ALS). The company has aligned with the regulator on submission content and structure, targeting an early December 2026 filing. Health Canada indicated no concerns with this timeline. PrimeC is supported by Phase 2b PARADIGM data showing a ~15-month median survival benefit and biomarker improvements. NeuroSense is also preparing for its confirmatory Phase 3 PARAGON trial in the U.S. The company operates as a late-stage clinical biotechnology firm developing disease-modifying treatments for neurodegenerative diseases.

On June 29, 2026, NeuroSense Therapeutics announced that its Phase 2b study for Amyotrophic Lateral Sclerosis (ALS) achieved its primary endpoint, demonstrating a statistically significant reduction of TDP-43, a defining pathological hallmark of the disease. The company incorporated the results into several existing Registration Statements on Form S-8 and Form F-3. NeuroSense Therapeutics is a biotechnology company developing therapeutics for neurological disorders.

NeuroSense Therapeutics Ltd. reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study evaluating PrimeC for the treatment of Alzheimer’s disease. The announcement was made via a press release on June 25, 2026. NeuroSense is a biopharmaceutical company focused on developing therapies for neurological disorders.